Syndicate Bio is a platform biotech building the world's most diverse human-genomic datasets — sequencing African populations at scale via co-funded pharma consortia — to feed drug discovery pipelines that today rely on <2% African representation. The wedge is a pre-competitive consortium model (Roche/GSK/Regeneron underwrite dataset build, Syndicate operates on the ground, all parties get query rights), positioning Syndicate as the "Africa arm" global pharma has failed to build directly — Roche's own Africa genomics unit has recruited under 20K participants since 2017, while founder Abasi Ene-Obong previously scaled to 100K+ in Nigeria at 54gene inside two years.
Validation: SOPHiA GENETICS named Syndicate its first liquid biopsy customer in Africa (April 2024); Syndicate signed MoUs with the Nigerian Institute of Medical Research (NIMR) and the National Institute for Cancer Research and Treatment (NICRAT) for oncology and drug-discovery work; Ene-Obong was named to the TIME100 Health 2025 list. StoryHouse Fund I wrote a $125K SAFE on a $5M cap at Pre-Round (2023-10-26) alongside Resilience17, TCVP (Gbenga Oyebode), and Techstars. The position was marked down 20% in 12/2025 and topped up via a $300K milestone-tranched Pre-Seed Extension from Fund II at a $4M cap — reflecting slower-than-hoped revenue traction (est. LTM <$100K, 6-month runway) against real strategic momentum.
Syndicate operates at the intersection of a large, fast-growing precision-medicine market and a specific data-scarcity arbitrage. The addressable prize is not the MEA genomics service line ($1.24B, single-digit share upside) but the value pharma places on diverse-population targets that unlock the next generation of drugs — UK Biobank pulled >$300M of pharma funding for a European cohort; African cohorts carry higher information density per genome (more variance, shorter linkage-disequilibrium blocks) and could plausibly command comparable or higher pharma budgets over the next decade.
| Player | Positioning | Funding | Edge vs. Syndicate |
|---|---|---|---|
| Syndicate Bio | African-led pre-competitive consortium; whole-genome sequencing at scale; SOPHiA liquid biopsy partner in Africa | $1.2M raised (Pre-Round) | — |
| 54gene (defunct) | Predecessor African biobank; drug-discovery model licensing targets | Shut down Sept 2023 | Same founder — assets now inaccessible; a cautionary tale on operational execution |
| Roche Africa Genomics Unit | Corporate-run African genomics initiative since 2017 | Internal corporate | Balance-sheet scale, but under 20K participants recruited in ~7 years — infrastructure deficit |
| SOPHiA GENETICS | Global genomic-analysis platform in ~70 countries, partnering rather than competing in Africa | NASDAQ-listed (SOPH) | Bioinformatics scale; chose Syndicate as African channel partner rather than build direct |
| Sub-Saharan genomics startups (3X4 Genetics, Next Biosciences, IndyGeneUS, Synexa) | Consumer/clinical genetics point solutions | Mostly seed-stage | Narrower scope — none pursuing pan-African pharma-consortium data build |
Moat: Founder-embedded operational infrastructure across Nigerian teaching hospitals plus MoU-level access to NIMR/NICRAT gates the pan-African data build against foreign entrants; the moat is real but contingent on founder retention and revenue execution.
Commercial revenue lags the strategic footprint. The Fund II tranche structure ($100K released only on two consecutive months of $50K MRR) is StoryHouse's explicit forcing function on that gap. Consortium contracts with Roche/GSK/Regeneron discussed in 2023 diligence remain in the pipeline in the public record but have not converted to disclosed revenue.
Founder's stated exit thesis in diligence pointed to a Roche/GSK/Regeneron/Amgen acquisition analog to Amgen–deCODE ($400M) or GSK's $300M investment in 23andMe, with a $500M–$1B range if a competitive bidding dynamic materializes. The realistic bear case is that consortium contracts never mature to platform revenue and the outcome is either a talent-and-assets acquihire or the structured 3x return on the tranched extension triggering off partial revenue milestones. StoryHouse Fund I return is the smaller of (a) 3x on $125K if $2M cumulative revenue is booked, or (b) equity-scaled pro-rata upside — capped by the 12/2025 markdown at a $4M reference.
Real talk conversation — shared with him my frustration with the lack of communication.
He shared how challenging this fundraising environment has been; how he's personally been putting money into the business; how his team has been going without salary; how optimistic he is given the market demand.
He feels like there's an asterisk next to his name.
I put the ball in his court — I told him to get back to me on what would be helpful for him check-size wise, but that he would also need to incentivize us because I am very busy right now. The ball is in his court.
Follow-up questions when we chat this weekend or early next week: How much have you put into the business personally? How long have your different staff gone without salaries? What are their personal situations? How long could you reasonably bootstrap another $100K? Are there any team members who aren't absolutely essential to closing these partnerships right now? In the event of a merger, what would that look like from our ownership position in Syndicate Bio?
September 2023 plan. Planning to do the $500K raise, do any extra at the $10M. He had meeting with SOPHiA Genetics; maybe raise opportunistically if one of these partnerships comes through — Endeavor, SOPHiA Genetics.
Liquid biopsy and data play. They operate in 70 countries but they don't operate in Africa. The deal they did with MSK (Memorial Sloan Kettering); they do a blood draw to sequence oncology genes from a blood sample. SOPHiA would like for Syndicate to be their Africa partner. AstraZeneca would fund the local ecosystem; SOPHiA would handle some of the bioinformatics. Syndicate keeps data, SOPHiA and AstraZeneca would have access to the data.
Has Maya signed yet?
Let's talk through the rest of these folks; DCVC feedback was surprising to me given the conversation. Stacking SAFEs is more challenging in this environment. What can you accomplish with $500K? What can you accomplish with $2.5M? Who are the most relevant Genomics businesses?
Abasi's responses to Miles' FF questions.
Are there any examples of other companies with the pre-competitive model route? Who are they? What are the downsides to the pre-competitive route in your view?
There aren't many companies in this space and where they exist they have typically occurred via a partnership between a private company and government (such as the UK Biobank and FinnGen). The UK Biobank has been able to bring on more than $300M in funding from pharma companies and FinnGen led to the spin-off and launch of Maze Therapeutics, which has received over $200M in funding from A16Z and others. MT's drugs under development are from genomic insights from the FinnGen data, which they built using a precompetitive model.
The major downside of a pre-competitive model is that the company facilitating it may not be able to capitalize on the data in a timely manner and as such lose out compared to other fast movers. This was why we did not use this model previously — we were still gaining experience in some of the needed capabilities. Now we have developed the experience and can "run fast" rather than learn when others are running fast. Most of the datasets where the pre-competitive model was used were largely European, so the insights were incremental. In our case we will be unlocking genetic diversity like the world has not witnessed (African datasets make up less than 2% of genomic data available; ~95% of African ethnolinguistic groups have not yet been sequenced). Loss-of-function variants that led to Praluent, Repatha, and Evenity are more common in diverse populations, and the shorter linkage-disequilibrium blocks in Africans make their data better for fine-mapping.
Who are the other prospective partners likely had conversations with who are pursuing the African genome opportunity but are found deficient? Roche, 23andMe, and a few other pharma companies. There are a few reasons: (1) Infrastructure — largely non-existent in Africa; we were the first at 54 to build it for scale. (2) Historical experience of extractive science — US NIH, Gates Foundation, and Harvard/Broad Institute historically collected samples but sent them to US/European biobanks; African researchers and governments are now kicking back. SOPHiA Genetics is operational in ~70 countries but not present in Africa and would like to be — their CFO/COO Ross Muken is leading an engagement to partner with us. (3) Trust — 23andMe's "Trojan Horse" South Africa program was called out publicly; Pfizer's Nigeria clinical trial history has left a bad taste. This is one of the reasons pharma is looking for an "African company" to lead this.
Separately, this is hard work — infrastructural, logistical, financial, ethical, social, and scientific challenges in a difficult operating environment. With 54 my focus was on proving this can be done; now that I have learned first hand, it's easier to do it while building the business to sustain it.